May 20th, 2015 – by Nuala MoranReal world evidence holds the potential to both increase efficiency in R&D and to bridge the gap between the proof of efficacy required to pass regulatory scrutiny and the demonstration of likely effectiveness needed to satisfy health technology assessment bodies, says Professor Sarah Garner, Associate Director for Science Policy and Research at NICE.
Kenneth Oye Professor of Political Science and Engeneering Systems, MIT Kenneth Oye holds a joint appointment in Political Science and Engineering Systems, with research and teaching on international relations, political economy and technology policy. His books include Cooperation under Anarchy, Economic Discrimination and Political Exchange, and the “Eagle” monographs on American foreign policy. His recent [...]
Irene Norstedt Acting Executive Director, IMI The IMI Governing Board appointed Irene Norstedt as Acting Executive Director of IMI as of 16 December 2014. Irene Norstedt comes from the European Commission, where she was Head of the Innovative and Personalised Medicine Unit at the European Commission’s Directorate-General for Research and Innovation. She has been at [...]
Barbara Lopez Kunz Global Chief Executive, DIA Barbara Lopez Kunz is leading the transformation of DIA through developing and implementing a strategy that focuses on driving innovation to improve the health of people worldwide. She is responsible for the leadership and oversight of DIA global operations and is accountable to the DIA Board of Directors. [...]
Gigi Hirsch, M.D. Executive Director, MIT Center for Biomedical Innovation Dr. Hirsch is the Executive Director of the MIT Center for Biomedical Innovation (CBI)which catalyzes and leads collaborative research programs involving faculty and students from across MIT’s campus as well as external stakeholders from the global healthcare and pharmaceutical industries. Her current efforts at CBI [...]
Ruxandra Draghia-Akli, MD, PhD Director of the Health Directorate, Research DG of the European Commission Previously, Ruxandra Draghia-Akli served as Vice President of Research at VGX Pharmaceuticals (now Inovio) and VGX Animal Health. Dr. Draghia's research activities have focused on molecular biology, gene therapy and vaccination. She is recognised as a global leader in the [...]
Magda Chelbus Director of Science Policy, European Federation of Pharmaceutical Industries and Associations (EFPIA) Magda Chlebus is in charge of policy and legislative debates which shape the research environment in Europe. This includes public-private collaborations (including the Innovative Medicines Initiative) and enabling and sensitive technologies. She joined EFPIA in 1995. Her experience covers public and [...]
Marc Berger Vice President Real World Data, Pfizer Marc L. Berger, M.D. is Vice President, Real World Data and Analytics at Pfizer. During his career, he has held a variety of leadership positions at OptumInsight, Eli Lilly and Company, and Merck & Co., Inc. His professional activities have included serving on the Medicare Evidence Development [...]
Better Science, Better Health: New Healthcare Models Join the conversation on twitter #BSBH15 Speakers: Click on the pictures for the biograhies Sabine Atzor, Director Regulatory Affairs, Part time seconded from F.Hoffmann-La Roche to EFPIA Richard Barker Founding Director, CASMI [...]
Better Science, Better Health: New Healthcare Models Join the conversation on twitter #BSBH15 Agenda: October 26th, 2015, Washington DC Hotel George 7:00 pm Cocktail Reception Kindly sponsored by Pfizer & DIA October 27th, 2015, Washington DC Cannon House Office Building, Cannon Caucas Room 8:00- 9:00 [...]